Date: Jul. 1	.1 th , 2022	
Your Name:	Yirui Zhai	
Manuscript Titl	le: The epidemic of malignant mesothelioma in China: a prediction of incidence during	2016-2030
Manuscript nur	mber (if known): TLCR-22-233	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T	ime frame: Since the initial planning of th	ne work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03] CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011] Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000]	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript		
	writing or educational events	V	
6	Payment for expert testimony	XNone	
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
4.5	5		
13	Other financial or non-financial	XNone	
	interests		

This work was supported by Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011]; Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000].

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Jul. 11 ^t	^h , 2022	
Your Na	ame:	Zhouguang Hui	
Manus	cript Title	The epidemic of malignant mesothelioma in China: a prediction of incidence during 20	016-2030
Manus	cript num	ber (if known): TLCR-22-233	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Т	ime frame: Since the initial planning of th	ne work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03] CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011] Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000]	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
C	Payment for expert testimony	X None	
6	Payment for expert testimony	xNone	
7	Support for attending meetings	XNone	
	and/or travel		
	·		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
	whichig, girts or other services		
13	Other financial or non-financial	X None	
13	interests		

This work was supported by Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011]; Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000].

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Jul. 11 ^t	, 2022	
Your N	ame:	Wanging Chen	
Manus	cript Title:	The epidemic of malignant mesothelioma in China: a prediction of incidence during 20	16-2030
Manus	cript num	per (if known): TLCR-22-233	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Т	ime frame: Since the initial planning of th	ne work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03] CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011] Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000]	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript		
	writing or educational events	V	
6	Payment for expert testimony	XNone	
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
4.5	5		
13	Other financial or non-financial	XNone	
	interests		

This work was supported by Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011]; Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000].

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Jul. 11th</u>	, 2022	
Your Name:	Jianming Ying	
Manuscript Title:	The epidemic of malignant mesothelioma in China: a prediction of incidence dur	ing 2016-2030
Manuscript numb	per (if known): TLCR-22-233	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T	ime frame: Since the initial planning of th	ne work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03] CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011] Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000]	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
C	Payment for expert testimony	X None	
6	Payment for expert testimony	xNone	
7	Support for attending meetings	XNone	
	and/or travel		
	·		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
	whichig, girts or other services		
13	Other financial or non-financial	X None	
13	interests		

This work was supported by Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011]; Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000].

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>Jul. 11th, 2022</u>		
Your Name: <u>Junlin</u>	ng Li	
Manuscript Title:	The epidemic of malignant mesothelioma in China: a prediction of incidence	during 2016-2030
Manuscript number (if	known): TLCR-22-233	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03] CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011] Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000]		
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
C	Payment for expert testimony	X None	
6	Payment for expert testimony	xNone	
7	Support for attending meetings	XNone	
	and/or travel		
	·		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
	whichig, girts or other services		
13	Other financial or non-financial	X None	
13	interests		

This work was supported by Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011]; Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000].

Please place an "X" next to the following statement to indicate your agreement:

Date: _	Jul. 11 ^t	, 2022	
Your Na	ame:	Shugeng Gao	
Manus	cript Title:	The epidemic of malignant mesothelioma in China: a prediction of incidence during 2	016-2030
Manus	cript num	per (if known): TLCR-22-233	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03] CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011] Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000]		
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript		
	writing or educational events	V	
6	Payment for expert testimony	XNone	
_		V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	XNone	
	other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
4.5		· · ·	
13	Other financial or non-financial	XNone	
	interests		

This work was supported by Beijing Hope Run Special Fund of Cancer Foundation of China [LC2016L03]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-011]; Clinical Application Project of Beijing Municipal Commission of Science and Technology [Z171100001017114] and National key research and development program [1311002, 2017YFC1311000].

Please place an "X" next to the following statement to indicate your agreement: